# Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus

> **NCT04697485** · PHASE4 · WITHDRAWN · sponsor: **Northwestern University**

## Conditions studied

- HF - Heart Failure
- Diabetes Mellitus

## Interventions

- **DRUG:** Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg

## Key facts

- **NCT ID:** NCT04697485
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-08
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-03-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Enrollment and funding challenges
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04697485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04697485, "Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04697485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*